Antimicrobial resistance detection
Real-time PCR solutions to detect AMR in Candida auris and Mycoplasma genitalium
ELITechGroup MDx (EGMDx) offers four real-time PCR solutions to detect and discriminate resistance associated mutations for both Candida auris and Mycoplasma genitalium. MGB Alert® reagents utilize minor groove binder probe technology, and feature flexibility of PCR-based detection and/or melt curve analysis. Mutations for these four products are detected by post-PCR melt curve analysis.
Candida auris resistance detection
C. auris is a globally distributed pathogenic yeast that can cause invasive candidiasis, especially affecting critically ill and immunocompromised patients. C. auris often exhibits multidrug resistance to fluconazole and variable susceptibility to echinocandins, other azoles, and amphotericin B. C. auris infections in the US nearly doubled between 2019 and 2021, with more than half the states reporting incidence.
Rising incidence combined with its high outbreak potential led both the CDC and WHO to list C. auris as an urgent antimicrobial threat (CDC, 2019) and a critical priority group fungal pathogen (WHO, 2022). The CDC highlights the need for improved detection and infection control practices to prevent the spread of C. auris.
Mycoplasma genitalium resistance detection
M. genitalium is a sexually transmitted bacterium causing urethritis in men and associated with cervicitis and pelvic inflammatory disease in women. Recommended treatment from the CDC for M. genitalium infections is doxycycline followed by either azithromycin, if macrolide sensitive, or moxifloxacin if macrolide resistant.
US prevalence of molecular markers for M. genitalium macrolide and fluoroquinolone resistance are as high as 90% and 15% respectively. When access to macrolide resistance testing is available, the CDC recommends resistance guided therapy for diagnosing and treating M. genitalium infections.
Product Ordering Information
CATALOG # | PRODUCT NAME | PRODUCT DESCRIPTION |
M400920 | MGB Alert Candida auris with echinocandin resistance RUO Detection Reagent | 20X mix of primers and probes to detect C. auris, differentiate echinocandin resistance mutations, and an internal control |
M400861 | MGB Alert Candida auris with fluconazole resistance RUO Detection Reagent | 20X mix of primers and probes to detect C. auris, differentiate fluconazole resistance mutations, and an internal control |
M400908 | MGB Alert M. genitalium with fluoroquinolone resistance RUO Detection Reagent | 20X mix of primers and probes to detect M. genitalium, differentiate fluoroquinolone resistance mutations, and an internal control |
M400860 | MGB Alert M. genitalium with macrolide resistance RUO Detection Reagent | 20X mix of primers and probes to detect M. genitalium, differentiate macrolide resistance mutations, and an internal control |
Research use only. Not for use in diagnostic procedures.
INFECTIOUS DISEASE TEST PORTFOLIO
Real-Time PCR testing for laboratories
ELITechGroup MDx set an industry standard in real-time PCR with the introduction of minor groove binder (MGB) probe technology, featured in our MGB Alert® products. MGB probe technology has long been the gold standard for hybridization probes that allow for melt curve analysis. Adding to our legacy of innovation, we now offer DSQ Alert™ probe technology, an evolution in MGB probe chemistry. Our DSQ Alert reagents feature our newest proprietary duplex stabilizing quencher chemistry in hydrolysis probes, offering enhanced signal-to-noise fluorescence and DNA duplex stability. All test reagents may be used on ELITechGroup MDx proprietary instrument systems and on most open channel platforms.
Our PCR offerings
- Adenovirus§
- Aspergillus spp.‡
- Babesia‡
- Bartonella‡
- BKV§
- Bordetella P/PP§
- Borrelia‡
- Borrelia RF‡
- Candida auris§
- C. auris with echinocandin resistance‡
- C. auris with fluconazole resistance‡
- Candida species‡
- Carbapenem-resistant Enterobacterales (CRE)‡
- Chikungunya‡
- Chlamydia pneumoniae‡
- CMV§
- Coccidioides‡
- Cryptococcus species‡
- Dengue 1-4‡
- EBV§
- Ehrlichia/Anaplasma‡
- Enterovirus§
- GUD-1 HSV 1&2 / T. pallidum‡
- GUD-2 H. ducreyi /
C. trachomatis L1-3‡ - Hepatitis E virus‡
- HHV-6§
- HHV-8§
- Histoplasma/Blastomyces‡
- hMPV§
- HSV 1&2*
- Influenza A/B/RSV‡
- JCV§
- Legionella pneumophila§
- Legionella species§
- Malaria‡
- MG with fluoroquinolone resistance‡
- MG with macrolide resistance‡
- MPXV/OPXV‡
- MRSA/SA*
- Mucorales‡
- Mumps‡
- MTB speciation‡
- Mycoplasma pneumoniae‡
Master Mixes
In Development
- HT HDV
- HT HSV 1&2/VZV
- HT Legionella
- HT Norovirus GI/II
*IVD/EUA
§Analyte Specific Reagent. Analytical and performance characteristics are not established.
‡For Research Use Only. Not for use in diagnostic procedures.
MOLECULAR DIAGNOSTICS SYSTEM
The ELITe BeGenius®
Extraction, amplification, results.
With automated extraction, amplification, and results interpretation, the ELITe BeGenius is a sample-to-result solution for your lab. A 3-hour turnaround time means up to 3 hours of walkaway time per run.
Bring more power and flexibility into your lab.
Open mode allows a customizable workflow. 24 PCR wells offer independent thermocycling capability. The ELITe BeGenius features:
- Full automation with onboard extraction and real-time PCR
- Total nucleic acid extraction of RNA and DNA
- Open system capability
- 24 PCR wells, each with independent thermocycling capability
- Multiple tests from each eluate
- Post amplification melt curve option
- Qualitative and quantitative capable
- Up to 72 sample results in an 8-hour shift
- Onboard cooled storage of samples, eluates, and reagents
- 6 optical channels with cross-talk customization
- Automated results interpretation
- LIS integration
ELITechGroup Corporate
At a global corporate level, ELITechGroup is an integrated in-vitro diagnostics company that develops, manufactures and markets a wide range of diagnostic products and solutions, including reagents, instruments, and software. More than 650 employees make ELITechGroup a trusted partner in the IVD industry, serving hospitals and diagnostic laboratories in more than 100 countries through direct sales and third-party distribution.
To optimally serve customers in an ever-evolving IVD market, ELITechGroup is organized into four business units dedicated to specific IVD technologies and market segments: Molecular Diagnostics (MDx), Clinical Chemistry, Biomedical Systems, and Microbiology.
ELITechGroup Molecular Diagnostics US
ELITechGroup MDx LLC is the company’s US Molecular Diagnostics entity, based in Bothell, WA. The US MDx group serves the needs of clinical and research laboratories alike, offering an extensive range of molecular diagnostics products.
The US product portfolio includes the fully automated sample-to-result ELITe BeGenius instrument system and a growing menu of infectious disease tests and reagents that feature the innovative MGB Alert and DSQ Alert™ probe chemistries.
Why ELITechGroup?
Extensive IP portfolio
Inventors of MGB probes
cGMP compliant, ISO13485 certified
High throughput oligonucleotide manufacturing
25,000 sq. ft. corporate office in Bothell, WA